IFNA1 and lipodystrophy: Population pharmacokinetics and pharmacodynamic analyses of baricitinib in patients with SAVI, and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) showed a dose-dependent decrease in IFN biomarkers, which indicated the effect of baricitinib on type I IFN signaling (48).